Baxter International Inc (NYSE:BAX) SVP Sells $1,918,947.00 in Stock

Baxter International Inc (NYSE:BAX) SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of Baxter International Inc (NYSE BAX) traded up $1.21 on Friday, hitting $72.26. The stock had a trading volume of 2,822,805 shares, compared to its average volume of 2,900,000. The stock has a market cap of $39,370.00, a PE ratio of 39.06, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. Baxter International Inc has a twelve month low of $46.05 and a twelve month high of $72.26. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.89%. Baxter International’s dividend payout ratio (DPR) is 34.59%.

BAX has been the subject of several recent analyst reports. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price target for the company in a research note on Tuesday, October 24th. Royal Bank of Canada restated a “hold” rating and issued a $66.00 price target on shares of Baxter International in a research note on Wednesday, November 22nd. Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price target for the company in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. upgraded Baxter International from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Finally, BMO Capital Markets restated a “buy” rating and issued a $70.00 price target on shares of Baxter International in a research note on Friday, October 13th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Baxter International presently has a consensus rating of “Buy” and an average target price of $68.64.

Several institutional investors and hedge funds have recently modified their holdings of the company. Advisor Partners LLC raised its holdings in shares of Baxter International by 27.9% during the 4th quarter. Advisor Partners LLC now owns 16,668 shares of the medical instruments supplier’s stock worth $1,167,000 after acquiring an additional 3,641 shares in the last quarter. Whitnell & Co. raised its holdings in shares of Baxter International by 21.3% during the 4th quarter. Whitnell & Co. now owns 7,112 shares of the medical instruments supplier’s stock worth $460,000 after acquiring an additional 1,251 shares in the last quarter. Eqis Capital Management Inc. raised its holdings in shares of Baxter International by 52.6% during the 4th quarter. Eqis Capital Management Inc. now owns 17,520 shares of the medical instruments supplier’s stock worth $1,132,000 after acquiring an additional 6,042 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of Baxter International by 6.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 2,525,870 shares of the medical instruments supplier’s stock worth $163,305,000 after acquiring an additional 142,209 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Baxter International by 120.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 44,538 shares of the medical instruments supplier’s stock worth $2,879,000 after acquiring an additional 24,374 shares in the last quarter. 83.75% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/28/baxter-international-inc-bax-svp-sells-1918947-00-in-stock.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply